U.S. · TECH · SCIENCE
June 16, 20223 min read, 576 words
Published: June 16, 2022 | 3 min read, 576 words
Gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat children early enough to prevent th...